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Diabetes mellitus and its clinical association with dry eye and ocular
surface are becoming a frequent and sometimes complicate problem in
Ophthalmology. Epidemiological data show that an increase in the
number of patients with this association is expected following the trend
to rise of the disease. The present work reviews the clinical and functional
aspects of this problem. The observations indicate that metabolic,
neuropathic and vascular tissue damages lead to an inflammatory process
and functional degeneration. The physiopathological mechanism include
hyperglycemia, advanced glycated end product accumulation, oxidative
stress and inflammation mediated by NF-κB signaling pathways. Potential
treatments enlightened by those findings would include antioxidant,
anti-inflammatory, secretagogues and/or anabolic agents that would
mimic insulin effects.
ABSTRACT
INTRODUCTION
Diabetes mellitus along with aging are probably the major risk factors
responsible for ocular diseases(1-2). Besides the well-known complications,
as cataract and diabetic retinopathy, in the last fifteen years, it was better
characterized the relationship with dry eye and ocular surface disorders(3-6).
Considering the increasing incidence of diabetes mellitus and the
perspective of growing importance of its implications in ocular surface,
the present work will review the clinical and physiopathological aspects
of lacrimal gland and ocular surface dysfunctions in this disease(7-8).
Moreover, it will review the state of the art of experimental research in the
field and potential new treatments for those conditions.
Diabetes mellitus: an overview of the problem
Diabetes mellitus is the most common metabolic disease worldwide
and its hallmark is hyperglycemia. Despite periods of feeding and fasting,
plasma glucose remains within a narrow range between 4 and 7 mM (72 to
126 mg/dl) in normal individuals. This tight control is governed by the
balance between glucose absorption from the intestine, production by the
liver and uptake and metabolism by peripheral tissues. Insulin increases
glucose uptake in muscle and fat, and inhibits hepatic glucose production,
thus serving as the primary regulator of blood glucose concentration(9-10).
Type 1 diabetes results from the autoimmune destruction of pancreatic
β cells causing insulin deficiency. Type 2 diabetes accounts for >90% of
cases and is characterized by a triad of (a) resistance to insulin action on
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glucose uptake in peripheral tissues, especially skeletal
muscle and adipocytes, (b) impaired insulin action to inhibit
hepatic glucose production, and (c) dysregulated insulin se-
cretion(10). In most cases, Type 2 diabetes is a polygenic
disease with complex inheritance patterns(11). Environmental
factors, especially diet, physical activity, and age, interact
with genetic predisposition to affect disease prevalence. Sus-
ceptibility to both insulin resistance and insulin secretory
defects appear to be genetically determined(11). Defects in
insulin action precede the overt disease and are seen in non
diabetic relatives of diabetic subjects. Initially, increased
insulin secretion compensates for insulin resistance but overt
disease occurs over time as β cell compensation fails. Other
specific types of diabetes were added, including one due to
genetic defects in β-cell function and genetic defects in insu-
lin action, along with diseases of the exocrine pancreas, and
drug-induced or chemically induced diabetes. Finally, the
type of diabetes diagnosed during pregnancy, gestational
diabetes mellitus, was considered independently (Table 1).
Besides chronic hyperglycemia, all forms of diabetes are
characterized by the development of diabetes-specific micro-
vascular pathology in the retina, renal glomerulus and peri-
pheral nerve. As a consequence of its microvascular patho-
logy, diabetes is a leading cause of blindness, end stage renal
disease and a variety of debilitating neuropathies(12). Diabe-
tes is also associated with accelerated atherosclerotic macro-
vascular disease affecting arteries that supply the heart, brain
and lower extremities. As a result, patients with diabetes have
a much higher risk of myocardial infarction, stroke and limb
amputation. Large prospective clinical studies show a strong
relationship between glycemia and diabetic microvascular
complications in both type 1 and type 2 diabetes(13-14). Hyper-
glycemia and insulin resistance both seem to have important
roles in the pathogenesis of macrovascular complications(15-17).
Diabetes-specific microvascular disease in the retina, glo-
merulus and vasa nervorum has similar physiopathological
features. Early in the course of diabetes, intracellular hyper-
glycemia causes abnormalities in blood flow and increased
vascular permeability. This reflects decreased activity of vaso-
dilators such as nitric oxide, increased activity of vasocons-
trictors such as angiotensin II and endothelin-1, and elabora-
tion of permeability factors such as vascular endothelial gro-
wth factor (VEGF). Quantitative and qualitative abnormalities
of extracellular matrix contribute to an irreversible increase in
vascular permeability. With time, microvascular cell loss oc-
curs, in part as a result of programmed cell death, and there is
progressive capillary occlusion due both to extracellular ma-
trix overproduction induced by growth factors such as trans-
forming growth factor-β (TGF-β), and to deposition of extra-
vasated periodic acid-Schiff-positive plasma proteins. Hyper-
glycemia may also decrease production of trophic factors for
endothelial and neuronal cells. Together, these changes lead
to edema, ischemia and hypoxia-induced neovascularization
in the retina, proteinuria, mesangial matrix expansion and
glomerulosclerosis in the kidney, and multifocal axonal dege-
neration in peripheral nerves (Figure 1). Although microvas-
cular diabetic alterations have never been studied in lacrimal
gland or ocular surface, a well-known complication, in part
attributed to peripheral nerve degeneration, is diabetic neuro-
trophic keratopathy(18-19).
In diabetic arteries, endothelial dysfunction seems to in-
volve both insulin resistance specific to the phosphatidylino-
sitol-3 kinase/Akt pathway(20-23) and hyperglycemia(12). Path-
way-selective insulin resistance results in decreased endothelial
production of the antiatherogenic molecule nitric oxide, and
increased potentiation of proliferation of vascular smooth mus-
cle cells and production of plasminogen activator inhibitor-1
(PAI-1) via the RasRafMEK kinasemitogen-activated
protein (MAP) kinase pathway(20). Hyperglycemia itself also
inhibits production of nitric oxide in arterial endothelial cells(24)
and stimulates production of PAI-1(24) (Figure 2).
Table 1. Classification and observations on types of diabetes mellitus
Type Characteristic Clinical comment
Type 1 Autoimmune, previously Potential association
called juvenile or with other autoimmune
insulin-dependent diseases
diabetes mellitus
Type 2 Polygenic and influenced Increasing incidence
by environment associated with higher
life span and western
cultural habits
Gestational Aggressive clinical May persist after
progress pregnancy
Secondary Side effect of medications Causative disease or
or pancreas dysfunction medication may also
(e.g.; steroids, chronic influence ocular and
alcoholism) lacrimal function
Genetic Genetic defects in insulin Potential ocular
secretion or action associated
malformations Figure 1 - Biochemical mediators and events related to diabetesmellitus that lead to capillary occlusion and peripheral tissue damage
Hyperglycemia
NO Angiotensin - IIEndothelin - I
VEGF
TGF B
Trophic Factors for Endothelial
and Neuronal Cells
Vascular Permeability Extravasation of Plasma Proteins
Extracellular Matrix Overproduction Microvascular Cell Loss - Apoptosis
Capillary Occlusion
Degeneration of
Peripheral Neves Edema Ischemia
Hypoxia-induced
Neovascularization
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Figure 2 - Signaling mechanisms related to endothelial damage in diabetes
mellitus
Both insulin resistance and hyperglycemia also participate
in the pathogenesis of diabetic dyslipidemia, which is implica-
ted in dry eye and ocular surface disease in humans and animal
models(1,25). Hyperglycemia seems to cause raised levels of
atherogenic cholesterol-enriched apolipoprotein B-contai-
ning remnant particles by reducing expression of the heparan
sulphate proteoglycan perlecan on hepatocytes(15). Associa-
tions of atherosclerosis and atherosclerosis risk factors with
glycemia have been shown over a broad range of glucose to-
lerance, from normal to diabetic. Of interest, postprandial hy-
perglycemia may be more predictive of atherosclerosis than is
fasting plasma glucose level or hemoglobin A1c(26).
Another major consequence of the hyperglycemia and
oxidative stress observed in diabetes mellitus is the forma-
tion of compounds as a result of the chemical reaction of the
glucose with proteins. These compounds, known as AGEs
(advanced glycation end-products), accumulate and modify
the structure of the protein matrix of many different tissues
and activate pro-inflammatory cytokines leading to the cel-
lular damage associated with the complications of diabetes
in kidney, blood vessels, retina, lens and lacrimal gland(27-28).
The nuclear factor-kappaB (NF-κB) is a signaling protein,
whose activation cascade could be activated by hyperglyce-
mia, AGEs and/or oxidative stress. The cellular response in-
volves transcription of a large number of genes, associated
with cellular response to stress, such as the TNF-α, and inter-
leukin-1β and in a chronic condition it may lead to tissue
damage and organ dysfunction(29-30) (Figure 3).
The identification of AGEs on ocular tissues have sugges-
ted their association with diabetic complications(28,31). Despi-
te a clear correlation between AGEs and oxidative damage
and tissue dysfunction, the possibility of direct microvascu-
lar damage contribution on lacrimal gland or ocular surface
alterations in diabetes mellitus was not investigated.
It is now clear that aggressive control of hyperglycemia in
patients with type 1 and 2 diabetes can attenuate the deve-
lopment of chronic complications such as retinopathy and
nephropathy(13-14). At present, therapy for type 1 and 2 diabe-
tes relies mainly on several approaches intended to reduce
the hyperglycemia itself: sulphonylureas, metformin, peroxi-
some proliferator-activated receptor-γ (PPARγ) agonists
(thiazolidinediones), α-glucosidase inhibitor and insulin.
These therapies have limited efficacy, limited tolerability
and significant mechanism-based side effects. Of particular
concern is the tendency of most treatments to enhance weight
gain(7,32) (Table 2).
Impact of diabetes mellitus on ocular surface and tear film
The ocular surface alterations in diabetes mellitus have
been studied more carefully in the last 2 decades and their
reported complaints by diabetic patients are becoming more
frequent in the clinical daily practice and strategies for their
prevention and amelioration are increasingly recognized.
Clinical studies revealed the clinical manifestations of
diabetes mellitus, associated with lacrimal gland and ocular
surface dysfunctions related to dry eye syndrome(3-5).
Figure 3 - Extracellular stimuli for advanced glycated end products
production and NF-κB signaling activation, cytokines production and
tissue impairment
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sient visual acuity reduction due to tear film instability may
be also present(43).
The most frequent and measurable clinical findings are
reduced tear secretion, tear film instability, higher grade of
conjunctival squamous metaplasia, lower goblet cell density
and reduced corneal sensation, but diabetes mellitus also
reduces the lipid layer of the tear film(4-5,40,44).
The correlation between diabetes mellitus duration or
diabetic retinopathy and diabetic complications in the ocu-
lar surface is controversial in the medical literature(5,42,45).
Moreover, the probability of other ocular complications wor-
sening on later introduction of systemic insulin in the treat-
ment, as reported in diabetic retinopathy is not clear(46).
Experimental models for understanding exocrine gland
and ocular surface dysfunction in DM
Among the experimental animal models to study ocular
complications of diabetes mellitus, the most used are ro-
dents.
Table 2. Drugs for diabetes mellitus treatment and comments on their known mechanisms of action and potential ocular repercussions of
those drugs
Drug Mechanism of action Potential ocular implications
Sulphonylureas and related Increase insulin release Reduction of risk of diabetic
insulin secretagogues from pancreatic islets ocular complications(32)
Metformin Reduce hepatic Higher overall risk reduction
glucose production with lower side effects(32)
Peroxisome proliferator- Enhance insulin action Inhibition of IL-1 β, endothelial
activated receptor-γ agonists cells apoptosis and micro
(thiazolidinediones) vascular proliferation(82-83)
α-Glucosidase inhibitors Decrease the absorption Potential role on ocular tissue
and ingestion of carbohydrates development and metabolism(84-85)
from the intestine
Insulin Suppresses glucose production Reduction of risk of diabetic ocular
and augments glucose utilization complications(13).Tissue differentiation,
growth, metabolism and extrapancreatic
production(54,72)
Corneal and conjunctival epithelial alterations, persis-
tent epithelial defects, which are frequently associated with
evident fragility during intraocular surgeries, and potential
visual impairment due to corneal scaring have been obser-
ved(5,19,33-37). Those pathological alterations are not limited to
anterior layers of the cornea(38-39).
A potential explanation combines chronic tear secretion
deficiency, peripheral neuropathy and hyperglycemia leading
to corneal epitheliopathy with complications as hyperosmo-
larity punctate keratopathy, recurrent erosions, persistent epi-
thelial defects, neurotrophic keratopahty, wound healing de-
lay, and higher risk of microbial keratitis(40-42) (Figure 4).
Although with very heterogeneous clinical presentation
and course in population terms, diabetic patients frequently
complain of typical dry eye symptoms, such as burning and
foreign body sensation(5,42). In more severe cases, the combi-
nation with diabetic neurotrophic keratopathy would help to
explain the absence of symptoms or apparent tolerance to
dryness and epitheliopathy. In initial and mild cases, tran-
A B C
Figure 4 - (A) 36 years old male patient with DM type 1 for 6 years. His clinical profile included peripheral neuropathy, nephropathy and proliferative
diabetic retinopathy. His eye examination also revealed severely reduced visual acuity and Schirmer test lower than 2 mm in both eyes; (B) Slit
lamp aspect of ocular surface with corneal edema and cataracts; (C) Fluorescein dye revealed short tear film break-up time and punctuate keratitis.
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The systemic injection of alloxan or streptozotocin indu-
ces a toxic damage to pancreatic islets and leads to a condi-
tion similar to DM type 1(47-48). In addition, lower and early
doses of streptozotocin are able to simulate the conditions of
DM type 2(49). In diabetic rats, reduced tear film secretion,
cataracts and salivary gland dysfunction after 4-5 weeks,
corneal epithelia alterations and wound healing delay after
8-10 weeks, and histological damage of retina after 40 weeks
are the ocular diseases that have been reported(50-53).
The possibility that a direct toxic effect of streptozotocin
on peripheral tissues would be confounded with diabetic com-
plications was not proven in a recent study with rat lacrimal
glands(54).
Non-obese diabetic mice are spontaneous models of DM
type 1, however, the autoimmune process also directly invol-
ves exocrine glands. Moreover, dacryoadenitis has a higher
incidence and presents earlier in males (8 weeks of life) than
in females (30 weeks of life)(55-56).
The Goto-Kakizaki rat is a model of diabetes mellitus
type 2, with Wistar wild background. Its functional and cellu-
lar characterization of ocular surface damage and dry eye
after 13-15 weeks of life was recently described(57).
In streptozotocin diabetic rat, progressive histological
damage of lacrimal gland and lipofucsin-like deposits in
acinar cells were observed (unpublished data). The expres-
sion of insulin receptor and other signaling elements were
preserved at 4 weeks, their role attributed to metabolic con-
trol and cell proliferation, but their activation was impaired
in diabetic lacrimal and salivary glands(58-59). Other peptide
membrane receptors, as orexin, ghrelin and growth hormone
were also identified, however their functional aspects are
undetermined(60).
Comparable, but not exactly similar findings between rat
exorbital lacrimal gland and parotid and/or submandibular
salivary glands were also be observed in diabetes mellitus.
They include similar impact on histology, function ad signa-
ling mechanisms(58,61). Evidences of oxidative stress secon-
dary to hyperglicemia has been explored for a long time and
was suggested to contribute to cell damage and exocrine
gland dysfunction(28,62-63).
Hyperglycemia involves expression of the inflammatory
cytokines of the innate immune system, as TNF-α and IL-1β,
which are clearly involved in lacrimal gland impairment in
other animal models(28,64-65). A unified mechanism that links
hyperglicemia, oxidative stress, inflammation and LG dys-
function has been attributed to NF-κB signaling pathways(28).
The post-transcriptional events do not only respond to the
aggression but also amplify and perpetuate it (Figure 3).
Impairment of wound closure and cornea reepithelization
has been studied in diabetic animal models(66-68). Apart a
proven beneficial effect of growth factors on corneal epithe-
lium proliferation, it is clear that correction to a normogly-
cemic state and/or topical insulin ameliorates corneal reepi-
thelization(53,69-71). Moreover, studies with cultured epithelial
cells reveals that insulin is able to better preserve phenotypic
characteristics of corneal epithelia(72). Therefore, insulin acts
and promote its effects in a similar way as growth factors do.
An unexpected recent finding in the lacrimal gland of
streptozotocin-induced diabetic rat was the persistence of in-
sulin transcription, expression and secretion. This finding in-
cludes lacrimal gland as an extrapancreatic source of insulin,
even in conditions mimicking diabetes mellitus type 1(54,73).
Molecular mechanisms of diabetic alterations in ocular
surface and lacrimal gland
It had been suggested that one or more of the following
initial events may lead to the alterations described in the tear
film and ocular surface of diabetic patients: a) chronic hyper-
glycemia, b) corneal nerve damage and c) impairment on
insulin action.
Those events contribute to tissue injury and may create an
environment for inflammation, as a non-specific response
that increases and perpetuates the tissue injury. As observed
before, inflammatory proteins are produced and are impli-
cated in diabetic complications in the early and subclinical
stages of disease. The progressive peripheral neural damage
is an example of afferent and efferent neural signaling path-
way, that once damaged, as in neurotrophic keratitis inter-
rupts the anti-inflammatory neural feedback(74-76).
Insulin exerts important metabolic and mitogenic effects
on several target tissues through the mediation of nutrient
influx, energy storage, gene expression and protein synthe-
sis. Exocrine gland secretions such as tears, saliva and milk
contain insulin, which support the metabolism and growth of
these glands. Their relevance for corneal and lacrimal gland
epithelial cell proliferation and culture maintenance was also
indicated(59,77-78).
The identification of insulin in the tear film and the pre-
sence of both insulin and insulin-like growth factor-1 (IGF-1)
receptors in the human ocular surface reinforce this percep-
tion(79). Its also interesting to note that some growth factors
previously identified as epithelial growth promoters such as
epidermal and nerve growth factors, share similar mecha-
nisms of signal transduction with insulin(80).
In streptozotocin diabetes-induced animal models, a hi-
gher expression of AGE, its receptor and NF-κB in was de-
monstrated lacrimal gland and ocular surface compared to
controls, as being a result of hyperglycemia. These findings
suggest that more than to induce a signaling cascade that
leads to oxidative damage and inflammatory alterations, it
may impair routine biochemical intracellular events, culmi-
nating with reduced tear secretion and dry eye syndrome(28).
Corneal nerve alterations, probably caused by direct hy-
perglycemic and/or microvascular damage to the tissue lead
to neurotrophic lesion and block the feedback mechanism
that controls tear secretion(18,41). They seem to occur later in
the process, but certainly have a crucial role in severe presen-
tations of the diabetic dry eye.
Based on experimental studies and recently elucidated
mechanisms of disease, several potential treatments have
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been suggested for ocular surface alterations and dry eye
syndrome related to diabetes mellitus (Table 3). Anti-AGE
agents have shown a potential protective effect against renal
disease and retinopathy in the context of chronic hypergly-
cemia and AGE accumulation(81).
In response to oxidative damage, a clinical study indica-
ted that daily supplementation of vitamin C and E can impro-
ve some parameters of ocular surface evaluation in diabetic
patients(82).
Other potential treatments, although not clinically tested,
to revert diabetic local damage to lacrimal gland tissue,
would include aspirin, known for decades to counterpose
diabetic complications and recently demonstrated to inhibit
NF-κB signaling cascade(83-84). In the same way, PPAR γ ago-
nists may be useful to improve lacrimal gland secretion by
inhibition of IL-1β production of nitric oxide(85).
CONCLUSIONS
Following the projections, incidence of dry eye and ocu-
lar surface damage due to diabetes mellitus trends to increase,
following the rise of the disease in the future. By now, their
correlations with other diabetic complications were not esta-
blished since those clinical events have not been included as
parameters in large population studies of diabetes mellitus.
The treatment involves artificial tears and intensive care in
cases of corneal epithelial defects. The potential role of topi-
cal anti-inflammatory/oxidant or mitogenic therapy is being
addressed by experimental studies and may be confirmed in
longer and controlled clinical trials.
Better treatments and preventive strategies for dry eye
syndrome and ocular surface alterations related to diabetes
mellitus will be available with the fine understanding of their
specific mechanisms, involving hyperglycemia, and its many
consequences such as oxidative, inflammatory and neurotro-
phic damage.
RESUMO
O diabetes mellitus e sua associação clínica com olho seco e
doença da superfície ocular estão se tornando um problema
freqüente e muitas vezes complicado em oftalmologia. Os
dados epidemiológicos mostram que o número de casos deve
crescer acompanhando a tendência de aumento da incidência
da doença. Esse trabalho revê seus aspectos clínicos e funcio-
nais. As observações indicam que as lesões metabólicas, neu-
ropáticas e vasculares levam a um processo inflamatório e
degeneração funcional. Os mecanismos fisiopatológicos in-
cluem hiperglicemia, acúmulo de produtos finais de glico-
silação avançada, estresse oxidativo e inflamação mediada
pelas vias de sinalização do NF-kB. Os tratamentos poten-
ciais sugeridos por essas observações incluiriam antioxi-
dantes, antiinflamatórios, secretagogos e/ou agentes anabó-
licos com efeitos miméticos ao da insulina.
Descritores: Síndrome do olho seco/fisiopatologia; Diabe-
tes mellitus; Estresse oxidativo; Modelos animais; Lágrimas
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